Dr. Spigel on the Rationale Behind the PACIFIC Trial

David Spigel, MD
Published: Thursday, Mar 08, 2018



David Spigel, MD, chief scientific officer, director, Lung Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses the rationale behind the design of PACIFIC, a trial that investigated the use of durvalumab (Imfinzi) in patients with locally advanced, unresectable stage III lung cancer.

The aim of PACIFIC was whether or not you could add immunotherapy to standard therapy. The idea of giving immunotherapy after chemotherapy and radiation therapy was most likely due to safety concerns. Immune-related toxicities, namely pneumonitis, can result from agents like durvalumab, and pneumonitis can be seen with chemotherapy and radiation.

The design of PACIFIC had as much to do with caution than a scientific theory that immunotherapy following chemoradiation is the best way to administer the treatment, says Spigel. Now that the study has been proven effective, many are wondering if antigen release results with chemotherapy and radiation, making tumors more vulnerable to T-cell activity.
 


David Spigel, MD, chief scientific officer, director, Lung Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses the rationale behind the design of PACIFIC, a trial that investigated the use of durvalumab (Imfinzi) in patients with locally advanced, unresectable stage III lung cancer.

The aim of PACIFIC was whether or not you could add immunotherapy to standard therapy. The idea of giving immunotherapy after chemotherapy and radiation therapy was most likely due to safety concerns. Immune-related toxicities, namely pneumonitis, can result from agents like durvalumab, and pneumonitis can be seen with chemotherapy and radiation.

The design of PACIFIC had as much to do with caution than a scientific theory that immunotherapy following chemoradiation is the best way to administer the treatment, says Spigel. Now that the study has been proven effective, many are wondering if antigen release results with chemotherapy and radiation, making tumors more vulnerable to T-cell activity.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ALK-Positive NSCLC: Emerging Strategies to Inform Sequencing, Optimize Outcomes, and Address Unmet Clinical Needs Along the Disease ContinuumAug 29, 20181.5
Community Practice Connections™: Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient OutcomesAug 30, 20182.0
Publication Bottom Border
Border Publication
x